Aptevo Therapeutics Highlights Key 2019 Priorities
ADAPTIR™ Bispecific Antibody Candidates Poised to
APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia;
APVO210 Beginning Phase 1 Clinical Trial in Q1 2019;
ALG.APV-527 Progressing with CTA Submission in H2 2019
Projecting 1/3 Cash Burn Reduction in 2019
Launching New Growth Initiatives for IXINITY
“The past year represented a period of solid execution for Aptevo as we delivered on our goal of advancing our ADAPTIR platform to have key programs progressing in the clinic in 2019,” said
“Our commercial organization has also been very successful expanding our IXINITY business,” continued Mr. White. “With U.S. sales more than doubling in 2018 to approximately
“We project our cash burn rate in 2019 will be in the range of
Key 2019 Priorities:
Advance 3 products in the clinic over the next 18 months
- Continue enrollment in the Phase 1 clinical trial of APVO436, being investigated for the treatment of acute myeloid leukemia
- Commence dosing in the Phase 1 clinical trial of APVO210 investigating single- and multiple-ascending doses of APVO210; anticipated to commence Q1 2019
- Report preliminary Phase 1 safety data for APVO436; anticipated Q4 2019
- Report preliminary Phase 1 safety data for APVO210; anticipated Q4 2019
- File a CTA in
Europe for ALG.APV-527, in co-operation with our partnerAlligator Bioscience ; anticipated H2 2019
Drive growth of IXINITY
- Capture increased market share of Hemophilia B market with expanded U.S. sales of IXINITY
- Commence a post-marketing Phase 4 study of IXINITY in pediatric patients; anticipated Q3 2019
- Launch a 3,000 IU assay of IXINITY providing enhanced patient convenience; anticipated Q2 2019
Pursue partnerships for our assets
- Continue partnering discussions around the ADAPTIR platform and individual bispecific product candidates
- Commence distributor/partnership discussions around ex-US IXINITY opportunities
Mr. White continued, “With the exception of our ALG.APV-527 program, partnered with
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo’s outlook, financial performance or financial condition, Aptevo’s technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the
Source:
Senior Director, Investor Relations and Corporate Communications
206-859-6628 | JurchisonS@apvo.com
Source: Aptevo Therapeutics Inc.